
Cognition Therapeutics (CGTX) Stock Forecast & Price Target
Cognition Therapeutics (CGTX) Analyst Ratings
Bulls say
Cognition Therapeutics has reported a significant advancement in its lead program, Zervimesine, which is now supported by an expanded access program funded by an anonymous benefactor for dementia with Lewy bodies, enhancing its market potential. Additionally, the company has achieved over 50% enrollment in the Phase 2 START study of Zervimesine in early Alzheimer's disease, indicating robust progress in its clinical pursuits. Financially, Cognition maintains a strong operational runway into the second quarter of 2026, with managed R&D and G&A expenses demonstrating effective cost control despite a reduction in cash reserves.
Bears say
Cognition Therapeutics Inc is contending with significant market competition from existing or emerging therapies that may hinder its ability to penetrate the market and influence pricing strategies negatively. Additionally, the company faces potential risks related to inadequate patent protection for its technology and product candidate CT1812, which could limit its competitive advantage on a national and international scale. These factors collectively contribute to a negative outlook for the company's stock, as they may adversely affect its market position and revenue potential.
This aggregate rating is based on analysts' research of Cognition Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Cognition Therapeutics (CGTX) Analyst Forecast & Price Prediction
Start investing in Cognition Therapeutics (CGTX)
Order type
Buy in
Order amount
Est. shares
0 shares